Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3Dermatologic 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Urinary Bladder Neoplasms 11Prostatic Neoplasms 9Carcinoma, Renal Cell 9Melanoma 4Kidney Neoplasms 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Testicular Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Colorectal Neoplasms 2Urothelial Cancer 1Sarcoma 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Muscle-invasive Bladder Cancer 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Invasive Bladder Cancer 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1

Interventions

aldesleukin 43Sunitinib 42Cyclophosphamide 30Nivolumab 29pembrolizumab 27Everolimus 27Interferon-alpha 25Bevacizumab 23Sorafenib 22Interleukin-2 20fludarabine phosphate 19Radiotherapy 18Ipilimumab 18Filgrastim 18Axitinib 18Gene Expression Profiling 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14Radiosurgery 13fludarabine 11Doxorubicin 11Carboplatin 11Blood Specimen Collection 11temsirolimus 10atezolizumab 9Immunohistochemistry 9Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Kidney Neoplasms × tremelimumab × Genitourinary × Clear all
NCT02762006 2024-03-18

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

Case Comprehensive Cancer Center

Phase 1 Completed
29 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Cambridge University Hospitals NHS Foundation Trust

Unknown
1,800 enrolled
DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡